Robust portfolio

A novel pipeline

Pyxis Pipeline


Potential Indications



Phase 1

Most Recent Milestone Achieved

Next Milestone

Antibody-Drug Conjugates (ADCs)


Breast, Head and Neck, Lung, and Thyroid Cancer

Dosing Initiated in 1Q23

Preliminary Data in Early 2024

Immuno-Oncology (IO)


Bladder, Cholangio-carcinoma, Colorectal, and Kidney Cancer

Phase 1

Dosing Initiated in 2Q23

Preliminary Data in Late 2023

Multiple Modalities

Internal Discovery
& Joint Ventures
Solid and Heme
Paused Programs
Anti-CD123 ADC



Available for partnering

Anti-KLRG1 mAb

Solid Tumors


Available for partnering

Antibody-Drug Conjugates (ADCs)

In developing our ADCs, we identified promising tumor targets and acquired highly specific antibodies to these tumor targets. Our technology platform, Flexible Antibody Conjugation Technology (FACT), is designed to enable us to develop highly controlled ADCs. Our ADCs are designed to employ site-specific conjugation of potent cytotoxic payloads to highly selective antibodies for a precise drug-antibody ratio, or DAR, with an enhanced therapeutic index.

An ADC with a multipronged mechanism of action

PYX-201 is an ADC that binds to extradomain-B (EDB) fibronectin, a non-internalizing, integral component of the tumor stroma that is overexpressed in many malignancies and minimally expressed in most normal adult tissues. After binding, its highly cell-permeable auristatin payload is enzymatically released extracellularly in the tumor microenvironment, presumably diffusing into, and killing, nearby tumor cells​ and cells that form the supportive tumor infrastructure. Auristatin elicits an antitumor immune response by inducing immunogenic cell death and dendritic cell maturation. While its effects are primarily due to its non-internalizing activity, a fraction of PYX-201 may also be internalized, further enhancing its antitumor activity.

PYX-201 is currently being investigated in an open-label, multicenter, Phase 1 dose-escalation trial in patients with relapsed or refractory solid tumors. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for PYX-201 in pancreatic cancer. Learn more about the PYX-201-101 trial here.

Immuno-oncology (IO)

We are building a diverse portfolio of immunotherapies that target broad immune regulatory mechanisms as well as novel immune checkpoints with the potential to transform the cancer treatment landscape. Our approach draws from externally developed programs and our internal discovery engine based on the work of Pyxis Oncology’s founding scientist.

A complimentary approach to PD-1/PD-L1 targeted therapies

PYX-106 is a fully human monoclonal antibody designed to target Siglec-15, an immune suppressor that is broadly expressed across different tumor types as well as on macrophages. PYX-106 could address PD-1/PD-L1 non-responders across a variety of tumor types and may be integral in combination with other immunotherapies. 

PYX-106 demonstrated a significantly longer half-life of seven days in an exploratory, non-human primate study and a ten-fold greater binding affinity to Siglec-15 compared to current benchmarks in development, which could allow for less frequent dosing while maintaining optimal activity.

PYX-106 is currently being investigated in an open-label, multicenter, Phase 1 dose escalation in patients with advanced solid tumors. Learn more about the PYX-106-101 trial here.

Paused Programs

A superior ADC for the treatment of hematologic cancers

PYX-203 targets and binds to the interleukin-3 receptor, also known as CD123, a rapidly internalizing target that is overexpressed in hematologic cancers by leukemic blasts and stem cells. After internalization, its highly potent cyclopropylpyrroloindoline (CPI) payload is enzymatically released and trafficked to the nucleus, where it crosslinks DNA interstrands. CPI is engineered for enhanced tolerability and may allow PYX-203 to reach a broader patient population. CPI is resistant to drug efflux pumps and could confer superior cancer-killing activity. The antibody is also engineered to have a modified Fc region to mitigate off-tumor toxicity.

An IO strategy to relieve immune inhibition and activate an antitumor response

PYX-102 targets killer cell lectin-like receptor subfamily G member 1 (KLRG1), an inhibitory receptor expressed on T cells and natural killer (NK) cells. Its ligands, E- and N-cadherin are expressed in numerous solid cancers. By blocking KLRG1 signaling, PYX-102 may relieve immune inhibition in these tumors while rescuing KLRG1-mediated suppression of human CD8+ T cells. PYX-102 has significant potential as a monotherapy and in combination treatment strategies.


We are building a proprietary catalog of new targets as the foundation for the next generation of Pyxis Oncology ADCs and immuno-therapies. Building on the work by Pyxis Oncology’s founding scientist Dr. Tom Gajewski and applying innovative bioinformatics and translational tools, we are identifying tumor specific targets, including cell surface and stromal antigens. Further, our approach has the potential to uncover additional mechanisms relevant for immune modulation in the tumor microenvironment.

immuno cell
immuno cell blur